Bio-Techne Q4 Adjusted EPS $0.55, Inline, Sales $301.32M Miss $307.25M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Techne (NASDAQ:TECH) reported Q4 earnings of $0.55 per share, in line with analyst consensus. This is a 7.84% increase YoY. However, the company's quarterly sales of $301.32M missed the analyst consensus estimate of $307.25M by 1.93%. Sales increased by 4.54% YoY.
August 08, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bio-Techne's Q4 earnings met expectations, but sales missed analyst estimates. This mixed result may lead to uncertainty in the market.
Bio-Techne's earnings were in line with expectations, which is a positive signal. However, the company missed sales estimates, which could be a concern for investors. The mixed results may lead to uncertainty in the market, potentially impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100